Drug Profile


Alternative Names: Human recombinant methionyl leptin; Methionyl human leptin; Myalept; r-metHuLeptin; Recombinant methionyl human leptin

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator Amgen
  • Developer Aegerion Pharmaceuticals; Novelion Therapeutics; Shionogi; University of Texas Southwestern Medical Center
  • Class Adipokines; Antihyperglycaemics; Antihyperlipidaemics; Obesity therapies
  • Mechanism of Action Glucose modulators; Hormone modulators; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lipodystrophy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lipodystrophy
  • Phase I Type 1 diabetes mellitus
  • Discontinued Amenorrhoea

Most Recent Events

  • 22 Dec 2016 Preregistration for Lipodystrophy in European Union (SC)
  • 29 Nov 2016 QLT acquired Aegerion Pharmaceuticals and later QLT changed its name to Novelion Therapeutics
  • 15 Mar 2016 Aegerion Pharmaceuticals has patent protection for metreleptin in USA, Europe, Canada, Israel, Australia, New Zealand, Mexico, China, South Korea and Japan (Aegerion Pharmaceuticals, 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top